leisure time -WSS

leisure time

author：Wikipedia 2025-09-29 22:48:15 - browse：99

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： The Pandemic Treaty must support building strong health systems

leisure time

WSS

BMI, flaws aside, is found to be useful estimate of body fat in youth

Change Healthcare payments predicted restored March 15

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

ASCO: AstraZeneca says CAR

Ultragenyx gene therapy for rare liver ailment succeeds in late

Ionis drug prevents swelling attacks due to hereditary angioedema

knowledge

leisure time

Wikipedia

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

UnitedHealth quietly bought dozens of outpatient centers

The high cost of giving birth even with insurance

With trial win, GSK could get blood cancer drug back on market

Novavax promises a turnaround & Lilly roils the obesity market

With trial win, GSK could get blood cancer drug back on market

FDA approval of Sarepta Duchenne genetic therapy gives me hope

At ASCO, AstraZeneca reports strong data for breast cancer drug

Peter Hotez and the public health issue of online harassment

Change Healthcare payments predicted restored March 15

leisure time

Amylyx ALS drug fails large clinical trial

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Change Healthcare cyberattack prompts Medicare loan program

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Novo Nordisk obesity pill bests Wegovy in early trial

How to bring more disabled researchers into academia

focus

focus

leisure time

explore